ÜMMİHAN TOPAL, SEVİNÇ DAĞISTANLI, MERVE BOŞAT SÖNMEZ, SÜLEYMAN SÖNMEZ
Comprehensive Medicine - 2024;16(3):147-156
INTRODUCTION: Our aim is to demonstrate the effectiveness of percutaneous cholecystostomy (PC) in the treatment of patients with acute cholecystitis (AC) before and during the COVID-19 pandemic and to show that it is a safe procedure for healthcare professionals and patients. METHODS: Demographic, clinical and laboratory data, technical success of PC, clinical response to treatment, duration of hospital stay, of patients with AK who applied to our hospital and underwent PC procedure in a total of 24 months before and during the pandemic, one-month post-procedure observation, and complications were compared. Results: PC was applied to a total of 124 patients in the pre-pandemic period (52) and pandemic period (72) examined in the study. The median age was 73.5 (2593) in the pre-pandemic period, and 64 (2390) in the pandemic period, and the difference between these was found to be significant (p=0.004). Clinical improvement due to PC was detected in 43 (86%) patients in the pre-pandemic period, and in 61 (84.7%) patients in the pandemic period, no significant differences were detected between the two groups (p=1.000). The day of hospitalization median value was 3 (118) days in pandemic period, and 3 (1-30) days in the pandemic period, and no significant differences were detected between the groups (p=0.794). DISCUSSION AND CONCLUSION: PC treatment in patients with AC during the pandemic and pre-pandemic periods is effective and safe for both the patient and the healthcare professionals who perform the procedure.
